Kestra Medical Technologies CCO sells $642k in shares

Alfred J. Ford Jr., Chief Commercial Officer at Kestra Medical Technologies, sold 27,632 of the company's common shares in late July and early August 2026, generating roughly $642,523. The transactions took place over three days - July 30, July 31, and August 3 - with share prices fluctuating between $22.6108 and $23.9046. The sales were required to meet tax withholding obligations tied to the vesting and settlement of restricted stock units.

Ford's share sales came as Kestra Medical's stock price has jumped by 75% in the past year, reaching $28.02 near its 52-week high of $30. However, the stock appears overvalued according to InvestingPro analysis, ranking among companies on the Most Overvalued list. Kestra Medical remains unprofitable, with a negative earnings per share of $2.43 in the last twelve months.

Despite the share sales, Ford still holds 105,839 common shares in Kestra Medical Technologies. The company recently reported a 66% increase in revenue for its fiscal fourth quarter of 2026, reaching $28.64 million, exceeding the consensus estimate of $26.5 million. However, Kestra Medical also reported an adjusted loss per share of $0.67, wider than the expected loss of $0.58.

Investment firms have maintained positive ratings for Kestra Medical. Stifel reiterated its Buy rating, maintaining a price target of $30.00, citing strong growth and record prescriptions for the ASSURE wearable cardioverter-defibrillator. Wolfe Research also increased its price target to $30.00 from $29.00, highlighting the company's impressive execution.

JPMorgan initiated coverage with an Overweight rating, emphasizing Kestra's ASSURE WCD potential in a market dominated by a single incumbent. Oppenheimer rated the stock at Perform, recognizing the large addressable market and increasing market share against competitor ZOLL.